跳至內容

NITD008

維基百科,自由的百科全書
NITD008
臨床資料
商品名英語Drug nomenclatureNITD008
識別資訊
  • (2R,3R,4R,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
CAS號1044589-82-3  checkY
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C13H14N4O4
摩爾質量290.28 g·mol−1
3D模型(JSmol英語JSmol
  • C#C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C2N=CN=C3N)CO)O)O
  • InChI=1S/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/m1/s1
  • Key:NKRAIOQPSBRMOV-NRMKKVEVSA-N

NITD008是一種抗病毒藥物,屬於腺苷類似物(一種核苷類似物英語nucleoside analog)。它作為治療黃病毒英語flavivirus感染的潛在藥物被開發,並顯示出對很多相關病毒的廣譜活性,如登革熱病毒西尼羅河病毒黃熱病病毒波瓦桑病毒英語Powassan virus丙肝病毒克亞薩努爾森林病病毒英語克亚萨努尔森林病病毒鄂木斯克出血熱病毒英語Omsk hemorrhagic fever virus寨卡病毒[1][2][3]然而,雖然NITD008在臨床前的動物試驗中顯示出較大毒性,不適合人體試驗,但是它仍被用於新型病毒性疾病治療的研究中。[4]

參考文獻

[編輯]
  1. ^ Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, et al. An adenosine nucleoside inhibitor of dengue virus. Proceedings of the National Academy of Sciences of the United States of America. December 2009, 106 (48): 20435–9. Bibcode:2009PNAS..10620435Y. PMC 2787148可免費查閱. PMID 19918064. doi:10.1073/pnas.0907010106可免費查閱. 
  2. ^ Lo MK, Shi PY, Chen YL, Flint M, Spiropoulou CF. In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses. Antiviral Research. June 2016, 130: 46–9. PMC 5096641可免費查閱. PMID 27016316. doi:10.1016/j.antiviral.2016.03.013. 
  3. ^ Deng YQ, Zhang NN, Li CF, Tian M, Hao JN, Xie XP, et al. Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus. Open Forum Infectious Diseases. October 2016, 3 (4): ofw175. PMC 5063548可免費查閱. PMID 27747251. doi:10.1093/ofid/ofw175可免費查閱. 
  4. ^ Nelson J, Roe K, Orillo B, Shi PY, Verma S. Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection. Antiviral Research. October 2015, 122: 39–45. PMC 4853296可免費查閱. PMID 26225754. doi:10.1016/j.antiviral.2015.07.008.